<DOC>
	<DOCNO>NCT02581033</DOCNO>
	<brief_summary>Evaluation rate sustain virological response among HBeAg-negativechronic hepatitis B patient discontinue long-term NA therapy . During study participant cease prescribed medication , occur immediate effect enrol study . The duration cessation indefinite , unless clinically indicate NA therapy re-start . Participants monitor per protocol follow cessation , monitor clinic visit blood test monitor virological response . Clinical visit interval week 2 , week , 4 , week 8 , week 12 , week 18 , follow every 3 month 2 year participant complete trial . Once participant complete trial commence , aim indefinite cessation NA therapy .</brief_summary>
	<brief_title>Determinants Virological Response After Discontinuation Nucleoside Analogue Therapy Hepatitis B Patients</brief_title>
	<detailed_description>During study participant cease prescribed medication , occur immediate effect enrol study . The duration cessation indefinite , unless clinically indicate NA therapy re-start . Participants monitor per protocol follow cessation , monitor clinic visit blood test monitor virological response . Clinical visit interval week 2 , week , 4 , week 8 , week 12 , week 18 , follow every 3 month 2 year participant complete trial . Once participant complete trial commence , aim indefinite cessation NA therapy .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<criteria>Male Female , age &gt; 18 year Subjects must able understand agree comply prescribe intervention ( NA cessation ) , visit reliably communicate study personal adverse event Able provide inform consent . Chronic Hepatitis B virus infection HBeAg negative time initiation NA therapy Meet current APASL guideline consideration antiviral cessation : uninterrupted NA treatment &gt; 2 year undetectable serum HBV DNA three separate occasion &gt; = 6 month apart ( undetectable define value &lt; low limit detection use sensitive commercial PCR assay ) Normal serum ALT level ( accord upper limit normal local laboratory ) Minimal moderate liver fibrosis define : METAVIR liver fibrosis stage F0F3 inclusive prior initial NA therapy and/or Transient liver elastogram ( TLE ) ( Fibroscan ) &lt; /= 9.6 kPa screen HBeAg positive chronic hepatitis B time NA initiation HBV associate extra hepatic manifestation Documented suspected hepatocellular carcinoma ( HCC ) History decompensated liver disease Compensated cirrhosis define : METAVIR liver fibrosis stage 4 pretreatment biopsy ; OR TLE &gt; 9.6 kPa screen Coinfection HIV , HCV HDV Latrogenic disease relate immunosuppression ( e.g . treatment systemic glucocorticoid , TNFaantibodies , immunosuppressive drug ) Significant alcohol consumption ( &gt; 30 g/day woman &gt; 50 g/day men ) Current know history cancer within 5 year screen Pregnant breast feed Other know significant liver disease ( include limit haemochromatosis , autoimmune hepatitis , alcoholic liver disease ) Participation interventional trial Poor Venous access Suspected lack compliance Any medical social reason opinion investigator would make subject inappropriate study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>